Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.09.006
L. Pan, S. Le, Jian Li
Objective To investigate the clinical features and treatment of child patient with chronic myeloid leukemia (CML) and T315I mutation in the ABL1 kinase domain. Methods The clinical features, diagnosis and treatment of one child CML patient with T315I mutation in ABL1 kinase domain in Fujian Medical University Union Hospital were retrospectively analyzed, and the literature was reviewed. Results The patient was treated with imatinib and dasatinib. The BCR-ABLIS value decreased and then increased. The disease progressed to the accelerated phase. At the same time, the T315I mutation was detected in the ABL1 kinase domain, the harringtonine chemotherapy was used, and the condition of patient got better. But eventually the hematopoietic stem cell transplantation could not be performed, the CML progressed to the blast phase and the patient died half a year later. Conclusions The prognosis of children with CML and T315I mutation in ABL1 kinase domain is poor. In the absence of punatinib treatment, hematopoietic stem cell transplantation should be performed as soon as possible after chemotherapy, which may improve the prognosis. Key words: Leukemia, myeloid, chronic; Mutation; BCR-ABL fusion gene; Tyrosine kinase inhibitor
{"title":"Childhood chronic myeloid leukemia with T315I mutation in ABL1 kinase domain: report of one case and review of literature","authors":"L. Pan, S. Le, Jian Li","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.09.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.09.006","url":null,"abstract":"Objective \u0000To investigate the clinical features and treatment of child patient with chronic myeloid leukemia (CML) and T315I mutation in the ABL1 kinase domain. \u0000 \u0000 \u0000Methods \u0000The clinical features, diagnosis and treatment of one child CML patient with T315I mutation in ABL1 kinase domain in Fujian Medical University Union Hospital were retrospectively analyzed, and the literature was reviewed. \u0000 \u0000 \u0000Results \u0000The patient was treated with imatinib and dasatinib. The BCR-ABLIS value decreased and then increased. The disease progressed to the accelerated phase. At the same time, the T315I mutation was detected in the ABL1 kinase domain, the harringtonine chemotherapy was used, and the condition of patient got better. But eventually the hematopoietic stem cell transplantation could not be performed, the CML progressed to the blast phase and the patient died half a year later. \u0000 \u0000 \u0000Conclusions \u0000The prognosis of children with CML and T315I mutation in ABL1 kinase domain is poor. In the absence of punatinib treatment, hematopoietic stem cell transplantation should be performed as soon as possible after chemotherapy, which may improve the prognosis. \u0000 \u0000 \u0000Key words: \u0000Leukemia, myeloid, chronic; Mutation; BCR-ABL fusion gene; Tyrosine kinase inhibitor","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"538-540"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41671919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.09.005
Zhi-qiang Zhao, Lie-yang Wang, Xiaolan Liu, Jiangtao Wang, T. Guan, Zong Zhang, Yanhong Luo, L. Su
Objective To explore the factors influencing the mobilization and collection of autologous peripheral blood stem cells. Methods The clinical data of 62 patients who received autologous peripheral blood hematopoietic stem cell mobilization in Shanxi Provincial Cancer Hospital from April 2012 to March 2017 were collected. The effects of age, gender, disease type, chemotherapy cycle, disease status, different schemes and the number of CD34+ cells in peripheral blood of patients 1 d before collection on the number of CD34+ cells and the success rate of CD34+ cells collection were analyzed. Measurement data were compared by one-way ANOVA and t test; count data were compared by χ 2 test; multivariate analysis was performed by multiple linear regression analysis. Results There were statistically significant differences in the number of CD34+ cells between patients with chemotherapy >6 cycles and ≤6 cycles [(2.6±1.3)×106/kg vs. (5.8±2.2)×106/kg; t = 5.221, P 0.05). Multi-factor analysis showed that > 6 cycles chemotherapy before mobilization was the adverse factor affecting stem cell collection (b = -3.435, P < 0.01). Conclusions The effective mobilization and collection of autologous peripheral blood stem cells are related to the number of chemotherapy cycles before mobilization. The stem cell mobilization and collection should be conducted as soon as possible when the chemotherapy is ≤ 6 cycles and the patient reaches partial remission or above. In addition, peripheral blood CD34+ cell count should be monitored during mobilization. When the peripheral blood CD34+ cell count is > 10/μl, the collection could be started on the next day to obtain a better collection effect, so as to improve the success rate of collection. Key words: Hematopoietic stem cell mobilization; Peripheral blood stem cell transplantation; Transplantation, autologous
{"title":"Analysis of factors influencing the mobilization and collection of autologous peripheral blood stem cells","authors":"Zhi-qiang Zhao, Lie-yang Wang, Xiaolan Liu, Jiangtao Wang, T. Guan, Zong Zhang, Yanhong Luo, L. Su","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.09.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.09.005","url":null,"abstract":"Objective \u0000To explore the factors influencing the mobilization and collection of autologous peripheral blood stem cells. \u0000 \u0000 \u0000Methods \u0000The clinical data of 62 patients who received autologous peripheral blood hematopoietic stem cell mobilization in Shanxi Provincial Cancer Hospital from April 2012 to March 2017 were collected. The effects of age, gender, disease type, chemotherapy cycle, disease status, different schemes and the number of CD34+ cells in peripheral blood of patients 1 d before collection on the number of CD34+ cells and the success rate of CD34+ cells collection were analyzed. Measurement data were compared by one-way ANOVA and t test; count data were compared by χ 2 test; multivariate analysis was performed by multiple linear regression analysis. \u0000 \u0000 \u0000Results \u0000There were statistically significant differences in the number of CD34+ cells between patients with chemotherapy >6 cycles and ≤6 cycles [(2.6±1.3)×106/kg vs. (5.8±2.2)×106/kg; t = 5.221, P 0.05). Multi-factor analysis showed that > 6 cycles chemotherapy before mobilization was the adverse factor affecting stem cell collection (b = -3.435, P < 0.01). \u0000 \u0000 \u0000Conclusions \u0000The effective mobilization and collection of autologous peripheral blood stem cells are related to the number of chemotherapy cycles before mobilization. The stem cell mobilization and collection should be conducted as soon as possible when the chemotherapy is ≤ 6 cycles and the patient reaches partial remission or above. In addition, peripheral blood CD34+ cell count should be monitored during mobilization. When the peripheral blood CD34+ cell count is > 10/μl, the collection could be started on the next day to obtain a better collection effect, so as to improve the success rate of collection. \u0000 \u0000 \u0000Key words: \u0000Hematopoietic stem cell mobilization; Peripheral blood stem cell transplantation; Transplantation, autologous","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"533-537"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49141696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.09.002
Meng-jun Shan, Yi Fan, Yanglan Fang, Yutong Lu, Jia Chen, Yang Xu
Objective To explore the impact on efficacy and prognosis of low-risk and intermediate-risk acute myeloid leukemia (AML, non-M3) patients with complete remission (CR) treated by high-dose cytarabine (HD-Ara-C) or standard-dose cytarabine(SD-Ara-C) before haploidentical hematopoietic stem cell transplantation (Haplo-HSCT). Methods A retrospective analysis was performed on 71 low-risk and intermediate-risk adult AML patients in the First Affiliated Hospital of Soochow University from March 2008 to April 2017. All the patients were treated by consolidation regimens containing cytarabine before Haplo-HSCT. According to the dosages of cytarabine, the patients were divided into HD-Ara-C group and SD-Ara-C group. Kaplan-Meier method, log-rank test and Cox regression model were used to make survival analysis, and the prognosis and efficacy between the two groups were compared. Results Of the 71 patients, 43 were male and 28 were female, and the median age was 37 years (18-56 years). The median follow-up time was 39 months (6-119 months). Sixty-four patients were in first remission, and 7 patients were in second remission. At the end of follow-up, the 2-year cumulative incidence of recurrence (CIR), overall survival (OS) rate, progression-free survival (PFS) rate, and non-recurrent death (NRM) rate in SD-Ara-C group were 19.33%, 77.44%, 80.67%, and 17.29%, respectively, the 2-year CIR, OS rate, PFS rates and NRM rate in HD-Ara-C group were 6.29%, 79.90%, 93.71%, and 17.68%, respectively. There was no significant difference in CIR (P = 0.124), OS rate (P = 0.862), PFS rate (P = 0.124) and NRM rate (P = 0.734) between the two groups. The incidence of severe infection in HD-Ara-C group was higher than that in SD-Ara-C group after consolidation therapy [62.8% (22/35) vs. 27.8% (10/36), P = 0.03]. Conclusion Compared with SD-Ara-C, the consolidation therapy containing HD-Ara-C before Haplo-HSCT cannot significantly improve the prognosis of low-risk and intermediate-risk AML patients in CR, but would increase the risk of severe infection after intensive consolidation therapy. Key words: Leukemia, myeloid, acute; Hematopoietic stem cell transplantation; Cytarabine; Prognosis
{"title":"Effects of different doses of cytarabine consolidation therapy followed by haploidentical hematopoietic stem cell transplantation on low-risk and intermediate-risk acute myeloid leukemia patients","authors":"Meng-jun Shan, Yi Fan, Yanglan Fang, Yutong Lu, Jia Chen, Yang Xu","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.09.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.09.002","url":null,"abstract":"Objective \u0000To explore the impact on efficacy and prognosis of low-risk and intermediate-risk acute myeloid leukemia (AML, non-M3) patients with complete remission (CR) treated by high-dose cytarabine (HD-Ara-C) or standard-dose cytarabine(SD-Ara-C) before haploidentical hematopoietic stem cell transplantation (Haplo-HSCT). \u0000 \u0000 \u0000Methods \u0000A retrospective analysis was performed on 71 low-risk and intermediate-risk adult AML patients in the First Affiliated Hospital of Soochow University from March 2008 to April 2017. All the patients were treated by consolidation regimens containing cytarabine before Haplo-HSCT. According to the dosages of cytarabine, the patients were divided into HD-Ara-C group and SD-Ara-C group. Kaplan-Meier method, log-rank test and Cox regression model were used to make survival analysis, and the prognosis and efficacy between the two groups were compared. \u0000 \u0000 \u0000Results \u0000Of the 71 patients, 43 were male and 28 were female, and the median age was 37 years (18-56 years). The median follow-up time was 39 months (6-119 months). Sixty-four patients were in first remission, and 7 patients were in second remission. At the end of follow-up, the 2-year cumulative incidence of recurrence (CIR), overall survival (OS) rate, progression-free survival (PFS) rate, and non-recurrent death (NRM) rate in SD-Ara-C group were 19.33%, 77.44%, 80.67%, and 17.29%, respectively, the 2-year CIR, OS rate, PFS rates and NRM rate in HD-Ara-C group were 6.29%, 79.90%, 93.71%, and 17.68%, respectively. There was no significant difference in CIR (P = 0.124), OS rate (P = 0.862), PFS rate (P = 0.124) and NRM rate (P = 0.734) between the two groups. The incidence of severe infection in HD-Ara-C group was higher than that in SD-Ara-C group after consolidation therapy [62.8% (22/35) vs. 27.8% (10/36), P = 0.03]. \u0000 \u0000 \u0000Conclusion \u0000Compared with SD-Ara-C, the consolidation therapy containing HD-Ara-C before Haplo-HSCT cannot significantly improve the prognosis of low-risk and intermediate-risk AML patients in CR, but would increase the risk of severe infection after intensive consolidation therapy. \u0000 \u0000 \u0000Key words: \u0000Leukemia, myeloid, acute; Hematopoietic stem cell transplantation; Cytarabine; Prognosis","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"516-522"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47554446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Decitabine combined with chemotherapy in treatment of relapsed/refractory acute lymphocytic leukemia: report of one case and review of literature","authors":"Yongjin Zhi, Xiaobing Li, Jianyong Li, Zhengdong Wu, Jianfeng Zhu","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.09.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.09.009","url":null,"abstract":"目的 \u0000观察含地西他滨联合化疗方案治疗复发难治急性淋巴细胞白血病（ALL）的效果。 \u0000 \u0000 \u0000方法 \u0000采用含地西他滨联合化疗方案治疗南通大学附属泰州市人民医院1例复发难治ALL患者，观察其疗效，并复习相关文献。 \u0000 \u0000 \u0000结果 \u0000该例患者确诊后，应用含地西他滨方案治疗1个疗程后获得完全缓解（CR），且CR持续时间达8个月，不良反应能耐受，主要为2~3级血液学毒性，体能状态良好，经过后续治疗后总生存时间超过1年。 \u0000 \u0000 \u0000结论 \u0000应用联合地西他滨的化疗方案治疗复发难治ALL是安全的，显示出一定的临床疗效，为复发难治ALL的治疗提供了新的治疗策略。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"550-552"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43835815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.09.001
Wen-rong Huang
Multiple myeloma (MM) is a common hematological malignancy with renal impairment in approximately 50% of patients. Sever renal impairment occurs in 15%-20% of newly diagnosed multiple myeloma patients. 200 mg/m2 melphalan-based regimen (Mel 200 regimen) as conditioning regimen of autologous hematopoietic stem cell transplantation (AHCT) is suitable for multiple myeloma patients with mild or moderate renal impairment, and 400 mg/m2 melphalan-based regimen (Mel 140 regimen) is fit for multiple myeloma patients with severe renal impairment. As the first line therapy for multiple myeloma patients with renal impairment, AHCT can increase response depth, repair renal function and improve survival. AHCT is a safe and beneficial procedure for MM patients with renal failure. Key words: Multiple myeloma; Renal insufficiency; Hematopoietic stem cell transplantation
{"title":"Autologous hematopoietic stem cell transplantation for treatment of multiple myeloma patients with renal impairment","authors":"Wen-rong Huang","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.09.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.09.001","url":null,"abstract":"Multiple myeloma (MM) is a common hematological malignancy with renal impairment in approximately 50% of patients. Sever renal impairment occurs in 15%-20% of newly diagnosed multiple myeloma patients. 200 mg/m2 melphalan-based regimen (Mel 200 regimen) as conditioning regimen of autologous hematopoietic stem cell transplantation (AHCT) is suitable for multiple myeloma patients with mild or moderate renal impairment, and 400 mg/m2 melphalan-based regimen (Mel 140 regimen) is fit for multiple myeloma patients with severe renal impairment. As the first line therapy for multiple myeloma patients with renal impairment, AHCT can increase response depth, repair renal function and improve survival. AHCT is a safe and beneficial procedure for MM patients with renal failure. \u0000 \u0000 \u0000Key words: \u0000Multiple myeloma; Renal insufficiency; Hematopoietic stem cell transplantation","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"513-515"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48398881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Primary central nervous system lymphoma (PCNSL) is one of the subtypes of non-Hodgkin lymphoma, its most pathological type is diffuse large B-cell lymphoma. At present, the gold standard of PCNSL diagnosis is biopsy and pathological examination, but many patients cannot be diagnosed early due to high risk of puncture, patient compliance problems and lack of specific symptoms. PCNSL is sensitive to chemotherapy, but many patients cannot tolerate high-dose chemotherapy or develop drug resistance, leading to disease progression or recurrence. Therefore, the search and identification of biomarkers in cerebrospinal fluid for early diagnosis, efficacy judgment and prognosis monitoring are particularly important for improving the diagnosis and treatment of PCNSL. Key words: Central nervous system neoplasms; Lymphoma; Cerebrospinal fluid; Tumor markers, biological; Diagnosis
原发性中枢神经系统淋巴瘤(Primary central nervous system lymphoma, PCNSL)是非霍奇金淋巴瘤的亚型之一，其最典型的病理类型是弥漫性大b细胞淋巴瘤。目前，PCNSL诊断的金标准是活检和病理检查，但由于穿刺风险高、患者依从性问题和缺乏特异性症状，许多患者无法早期诊断。PCNSL对化疗敏感，但许多患者不能耐受大剂量化疗或产生耐药性，导致疾病进展或复发。因此，寻找和鉴定脑脊液中生物标志物进行早期诊断、疗效判断和预后监测，对于提高PCNSL的诊断和治疗水平尤为重要。关键词:中枢神经系统肿瘤;淋巴瘤;脑脊液;肿瘤标志物，生物学;诊断
{"title":"Progress of cerebrospinal fluid biomarkers in primary central nervous system lymphoma","authors":"Jinlong Wang, Xudong Zhang, Qingjiang Chen, Wu Xue","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.09.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.09.015","url":null,"abstract":"Primary central nervous system lymphoma (PCNSL) is one of the subtypes of non-Hodgkin lymphoma, its most pathological type is diffuse large B-cell lymphoma. At present, the gold standard of PCNSL diagnosis is biopsy and pathological examination, but many patients cannot be diagnosed early due to high risk of puncture, patient compliance problems and lack of specific symptoms. PCNSL is sensitive to chemotherapy, but many patients cannot tolerate high-dose chemotherapy or develop drug resistance, leading to disease progression or recurrence. Therefore, the search and identification of biomarkers in cerebrospinal fluid for early diagnosis, efficacy judgment and prognosis monitoring are particularly important for improving the diagnosis and treatment of PCNSL. \u0000 \u0000 \u0000Key words: \u0000Central nervous system neoplasms; Lymphoma; Cerebrospinal fluid; Tumor markers, biological; Diagnosis","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"565-568"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43190153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To explore the feasibility of allogeneic hematopoietic stem cell transplantation using stable schizophrenia patients as hematopoietic stem cell donors and the effect of schizophrenia treatment drug clozapine on allogeneic hematopoietic stem cell transplantation. Method: A retrospective analysis was conducted on the diagnosis and treatment process of a patient with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation using a stable patient with schizophrenia as a hematopoietic stem cell donor, and literature review was conducted. The patient, a 28 year old male, was diagnosed with acute lymphoblastic leukemia. After receiving standardized chemotherapy, the disease was completely relieved but could not be maintained. After successfully matching with a stable cell sister with schizophrenia, allogeneic hematopoietic stem cell transplantation was performed, and the process was smooth. After a follow-up of 12 years, the patient's general condition was good, the primary disease was cured, and the donor's condition of schizophrenia was stable. Conclusion: Stable mild schizophrenia patients, as hematopoietic stem cell donors and the schizophrenia treatment drug clozapine, do not affect the efficacy of allogeneic hematopoietic stem cell transplantation. It is feasible to attempt under limited donor conditions.
{"title":"Hematopoietic stem cell transplantation with a schizoid patient in stable condition as the donor for treatment of acute lymphoblastic leukemia: report of one case and review of literature","authors":"Ruipeng Guo","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.09.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.09.010","url":null,"abstract":"目的 \u0000探讨以病情稳定的精神分裂症患者作为造血干细胞供者的异基因造血干细胞移植的可行性及精神分裂症治疗药物氯氮平对异基因造血干细胞移植的影响。 \u0000 \u0000 \u0000方法 \u0000回顾性分析长治医学院附属和平医院收治的以精神分裂症病情稳定患者为造血干细胞供者行异基因造血干细胞移植的1例急性淋巴细胞白血病患者的诊治过程，并进行文献复习。 \u0000 \u0000 \u0000结果 \u0000患者，男性，28岁，确诊为急性淋巴细胞白血病，给予规范化疗后疾病虽完全缓解但不能维持，与患有精神分裂症但病情稳定的胞姐配型成功后行异基因造血干细胞移植，过程顺利。随访12年，患者一般情况良好，原发病得到了治愈，供者精神分裂症病情稳定。 \u0000 \u0000 \u0000结论 \u0000病情稳定的轻型精神分裂症患者作为造血干细胞供者及精神分裂症治疗药物氯氮平不影响异基因造血干细胞移植的疗效，在供者有限的情况下进行尝试是可行的。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"552-554"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49410921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.09.007
Feifei Liu, Jinlong Huang, Yang Liu, Yan V. Wang, G. Lai, Jianzhen Shen
Objective To analyze the clinical efficacy and safety of fludarabine combined with cyclophosphamide (FC) and fludarabine and cyclophosphamide combined with rituximab (FCR) in the treatment of chronic lymphocytic leukemia (CLL). Methods FCR regimen was selected as the experimental group, and FC regimen was selected as the control group. The studies were retrieved from PubMed, Cochrane Library, Embase, CNKI, Wangfang and VIP databases by computer and the references listed in these studies were further searched. The randomized controlled trials (RCT) meeting inclusive criteria were extracted, and the quality was evaluated and cross-checked independently according to Cochrane Handbook for Systematic Reviews of Interventions, and then the Meta-analysis was conducted by using StataMP 14.0 software. Results A total of 7 studies and 1 985 patients were included. The complete remission rate and overall response rate of FCR regimen were better than those of FC regimen, and the differences were statistically significant (RR = 1.89, 95% CI 1.64-2.18, P < 0.01; RR = 1.15, 95% CI 1.10-1.21, P < 0.01). In terms of grade Ⅲ-Ⅳ adverse reactions, the neutropenia of FCR regimen was more severe than that of FC regimen, and the difference was statistically significant (RR = 1.25, 95% CI 1.01-1.55, P = 0.004). Conclusion The FCR regimen has a better clinical outcome and prognosis than the FC regimen, and is accompanied by more severe grade Ⅲ-Ⅳ neutropenia. Key words: Leukemia, lymphoid; Cyclophosphamide; Rituximab; Fludarabine; Meta-analysis
{"title":"Efficacy of rituximab combined with cyclophosphamide and fludarabine in treatment of chronic lymphocytic leukemia: a Meta-analysis","authors":"Feifei Liu, Jinlong Huang, Yang Liu, Yan V. Wang, G. Lai, Jianzhen Shen","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.09.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.09.007","url":null,"abstract":"Objective \u0000To analyze the clinical efficacy and safety of fludarabine combined with cyclophosphamide (FC) and fludarabine and cyclophosphamide combined with rituximab (FCR) in the treatment of chronic lymphocytic leukemia (CLL). \u0000 \u0000 \u0000Methods \u0000FCR regimen was selected as the experimental group, and FC regimen was selected as the control group. The studies were retrieved from PubMed, Cochrane Library, Embase, CNKI, Wangfang and VIP databases by computer and the references listed in these studies were further searched. The randomized controlled trials (RCT) meeting inclusive criteria were extracted, and the quality was evaluated and cross-checked independently according to Cochrane Handbook for Systematic Reviews of Interventions, and then the Meta-analysis was conducted by using StataMP 14.0 software. \u0000 \u0000 \u0000Results \u0000A total of 7 studies and 1 985 patients were included. The complete remission rate and overall response rate of FCR regimen were better than those of FC regimen, and the differences were statistically significant (RR = 1.89, 95% CI 1.64-2.18, P < 0.01; RR = 1.15, 95% CI 1.10-1.21, P < 0.01). In terms of grade Ⅲ-Ⅳ adverse reactions, the neutropenia of FCR regimen was more severe than that of FC regimen, and the difference was statistically significant (RR = 1.25, 95% CI 1.01-1.55, P = 0.004). \u0000 \u0000 \u0000Conclusion \u0000The FCR regimen has a better clinical outcome and prognosis than the FC regimen, and is accompanied by more severe grade Ⅲ-Ⅳ neutropenia. \u0000 \u0000 \u0000Key words: \u0000Leukemia, lymphoid; Cyclophosphamide; Rituximab; Fludarabine; Meta-analysis","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"541-545"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44713232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：